The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
|Videos|August 25, 2020
How to classify disease activity in vitiligo patients
Author(s)Jessica Barry
Is your patient’s vitiligo stable, unstable or recalcitrant? Expert Seemal R. Desai, M.D., FAAD, discusses how he classifies disease activity in his practice.
Advertisement
In this video, Dr. Desai explores these three broad categories of disease activity and what they entail.
In case you missed it: What are your patient's goals? Dr. Desai discusses the importance of
More from Dr. Desai’s AAD VMX presentation: In our upcoming video, Dr. Desai covers best practices to employ when treating unstable vitiligo.
For more about AAD VMX,
Reference
Desai S. What's New in Vitiligo. Therapeutic Hotline. AAD VMX 2020; June 12, 2020.
Advertisement
Related to this article
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
In TRANQUILLO 2, 21.86% of patients taking ritlecitinib 100 mg achieved F-VASI75 at week 52 vs 2.40% with placebo, according to data presented at EADV 2026.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5